Zydus Lifesciences, a global leader in innovation-driven healthcare, has introduced ANVIMO (Letermovir) in India, a groundbreaking advancement in the prevention of Cytomegalovirus (CMV) infection for patients undergoing haematopoietic stem cell (HSCT) and kidney transplants.
Available in 240 mg and 480 mg dosages, ANVIMO provides a safer and more effective alternative to traditional CMV treatments like ganciclovir and valganciclovir, which often cause bone marrow suppression and toxicity.
CMV infection is a major challenge in transplant patients, frequently leading to graft failure, reduced survival rates, and prolonged hospital stays. Letermovir offers superior safety, reducing side effects while enhancing transplant outcomes. However, its high cost has long been a barrier, with the innovator drug priced at over ₹5 lakh per month in India. Zydus has changed this landscape by launching ANVIMO at 91% lower cost, making CMV prophylaxis significantly more affordable.
With proven bioequivalence to the innovator drug, ANVIMO ensures high-quality treatment at a fraction of the price. This breakthrough enables more transplant patients to access timely, effective care, reducing complications and improving survival rates. By transforming CMV prevention, Zydus is reinforcing its commitment to accessible and affordable healthcare, ensuring that more Indian patients receive the life-saving treatment they need.
